IASH Officers and Leadership
General Director: Instituto Mexicano de Salud Cardiovascular.
PAST POSITIONS: Professor of Medicine, (Cardiology) UNAM, 1972-2012.
Director Cardiology Services, Hospital General de México, 1990-2012, Senior Researcher, Level F, Institutos Mexicanos de Salud, 1990-2010.
Received his Ph.D. in pharmacology and toxicology from Tulane University in 1975. He did postdoctoral work at the University of Iowa from 1975-1977, where his research focused on neural control of the circulation in hypertension. Since 1977 Dr. Fink has been in the Department of Pharmacology and Toxicology at Michigan State University where he became a full professor in 1987. His research continues to focus on sympathetic mechanisms of blood pressure regulation in hypertension, but other important interests are the renin-angiotensin system, endothelin and the role of venous function and body fluid volume distribution in control of blood pressure. Throughout his career he has served on the editorial boards of numerous journals that publish cardiovascular science and been an active member of the American Heart Association Council for High Blood Pressure Research. He is now serving as the Chair of the Council and will continue in that role until 2015.
Is the Dewitt-Cordell Professor of Surgical Sciences at the Wake Forest University School of Medicine in Winston Salem, North Carolina. He holds joint appointments as Professor of Medicine-Nephrology and Physiology-Pharmacology at the same Medical Center. Ferrario has pioneered research in the function of angiotensin-(1-7), the role of the area postrema in the medulla oblongata as a site at which angiotensin II modulates the central control of baroreflexes, and provided new insights into the clinical mechanisms of angiotensin receptor blockers and angiotensin converting enzyme inhibitors. Ferrario is a co-founder of the Inter American Society of Hypertension (IASH), the founder of the Consortium for Southeastern Hypertension Control (COSEHC™), the recipient of numerous international awards including the Novartis Award for Hypertension Research bestowed by the AHA Council on Hypertension in 2009, the Ignacio Chaves Centennial Gold Medal of Honor by the National University of Mexico in 1998, the Harry Goldblatt Award for Cardiovascular Research by the AHA in 1979, the Robert Tigersted award from the American Society of Hypertension in 2001, the Lifetime Achievement Award from the IASH in 2001, the Corcoran Award from the AHA in 2007, and the R Tigersted and J Wright awards from the Finnish (2008) and Australian (2008) Societies of Hypertension, respectively. He has authored over 500 publication and 4 books.
Is Associate Professor in the Hypertension and Vascular Research Center at the Wake Forest University School of Medicine. After finishing her MD degree, Dr. Varagic received her Doctor of Philosophy degree in Pathophysiology at the University of Belgrade, Serbia. Her research interest focusses on understanding the role of tissue components of the renin-angiotensin-aldosterone system in target organ injury in hypertension, diabetes, and aging. Dr. Varagic is also a Director of the Preclinical Microultrasound and Photoacoustic Imaging Core overseeing a new Vevo LAZR Photoacoustic imaging platform for obtaining non-invasive and longitudinal anatomical, functional, physiological, and molecular data in preclinical rodent models. Dr Varagic is Fellow of the American Heart Association and serves on Editorial Boards of Journal of Hypertension, Therapeutic Advances in Cardiovascular Disease, and Cardiorenal Medicine.
Is the Billy S. Guyton Distinguished Professor, Professor of Physiology and Medicine, Director of the Cardiovascular-Renal Research Center, and Dean of the School of Graduate Studies in the Health Sciences at the University of Mississippi Medical Center in Jackson, MS. Dr. Granger has been a member of CHBPR for over 30 years and has served on numerous CHBPR for over 30 years and has served on numerous CHBPR committees including the Council Leadership Committee. Dr. Granger served as President of the American Physiology Society in 2012 and currently he is Chair of the Council on Hypertension Program Committee and he also serves on Leadership committee of the Inter-American Society of Hypertension. He has authored or co-authored over 250 peer-reviewed publications, many of them in the Hypertension journal and is currently an Associate Editor for Hypertension, and a Co-Editor on the eBook series entitled Integrative Systems Physiology.
Dr. Granger has received several awards including the 2010 AHA Distinguished Scientist Award, APSE.H. Starling Distinguished Lecture Award, APS Bodil M. Schmidt-Nielsen Distinguished Mentor and Scientist Award, Dahl Memorial Lecture of the AHA, American Society of Hypertension Young Scholar Award, the International Society of Hypertension Demuth Research Award, Inter-American Society of Hypertension Young Investigator Award, the Regulatory and Integrative Physiology Young Investigator Award of the APS Water and Electrolyte Section, the Harold Lamport Award of the Cardiovascular Section of the APS the Henry Pickering Bowditch Lecture of the APS, and the Established Investigator Award of the AHA.
Postgraduate studies in Biological Chemistry area, at the Faculty of Pharmacy and Biochemistry, University of Buenos Aires. Currently is full Professor of Biological Chemistry at the Faculty of Pharmacy and Biochemistry, University of Buenos Aires in Buenos Aires, Argentina. She is also a member of the Career Investigator of the National Council of Scientific and Technical Research (CONICET), Argentina. Her main research interests relates to angiotensin-(1-7), the main component of the depressor arm of the renin-angiotensin system, at the central level. Her research is also focused on Mas receptor regulation in physiological and pathological situations.
Is Physician-in-Chief of the Jewish General Hospital and Professor and Vice-Chair, Department of Medicine, McGill University. He has been Chair of the High Blood Pressure Research Council of the American Heart Association (AHA) and President of the International Society of Hypertension, and is currently President of Hypertension Canada, and Associate Editor of Hypertension, journal of AHA. He is author of more than 500 original peer-reviewed publications on mechanisms and management of hypertension, and has received many awards for his research and leadership.
Received his Ph.D. in 1966 at the University of Mississippi under the direction of Dr. Arthur Guyton. He served on the faculty of the University of Mississippi, University of Alabama at Birmingham. In 1988 he joined Tulane University as Professor and Chair of the Department of Physiology and Director of the Center for Biomedical Research Excellence in Hypertension and Renal Biology. Dr. Navar investigates hormonal and paracrine mechanisms regulating renal hemodynamics, glomerular filtration rate, and sodium excretion and how these are altered in angiotensin II dependent hypertension.
Dr. Navar is an active member of many societies including the American Physiological Society, ASN, AHA, ASH and IASH. He has served on study sections (NIH, VA, AHA) and on Editorial Boards for various journals including American Journal of Physiology and Hypertension.
Dr. Navar has received numerous awards including the Gottschalk Award and the Walter B. Cannon Award from APS, the Richard Bright Award from ASH, and the Excellence in Hypertension Research award from the Council for High Blood Pressure Research.
Is in private practice and does clinical research at the Trinity Hypertension & Metabolic Research Institute in Carrollton, Texas. He currently is a Clinical Assistant Professor at UT Southwestern Medical Center in Dallas, Clinical Associate Professor at Texas Woman’s University in Dallas and is an attending physician of Internal Medicine at Baylor Medical Center, in Carrollton.
Dr. Punzi received his medical degree and postgraduate training from the University of Buenos Aires, Argentina and completed fellowships in clinical and research hypertension at the University of Texas Southwestern Medical School, Parkland Memorial Hospital, and St. Paul Hospital, all in Dallas.
Dr. Punzi has been the primary investigator in more than 70 clinical trials. He has participated in the ValHeft, VALUE, and ALLHAT studies and currently serves as a member of the Inclusion, Exclusion, Retention Committee of the NIH sponsored Systolic Blood Pressure Intervention Trial (SPRINT Study).
A fellow of both the American College of Clinical Pharmacology and the American Society of Hypertension, Dr. Punzi is a member of the Council for High Blood Pressure Research of the American Heart Association, the American Society of Hypertension, the American Society for Clinical Pharmacology and Therapeutics and serves as the Chair of the Finance and Medical Affairs Committee of the Inter-American Society of Hypertension. He also serves as a reviewer for the Journal of Human Hypertension, Journal of Clinical Research and Pharmacoepidemiology, Journal of Geriatric Cardiovascular Medicine, Journal of Clinical Hypertension, Expert Opinion on Pharmacotherapy, and the American Journal of Hypertension. Dr. Punzi served 15 years as the chairman of the editorial committee for the Dallas Medical Journal. He has published numerous articles in medical journal. He has written numerous books chapters a book on hypertension and served as series editor for three volumes of Clinical Cardiovascular Therapeutics.
Maria Claudia Irigoyen, M.D., Ph.D: Dr. Irigoyen is Professor of the Cardiopulmology Department and Head of Experimental Hypertension Laboratory at the Heart Institute of the University of São Paulo Medical School. In 1984, she received her MD degree from the Catholic University of Rio Grande do Sul (PUCRS), and in 1990 she accomplished her doctorate at the University of São Paulo. She belonged to the faculty of the Department of Physiology at the Federal University of Rio Grande do Sul for over 15 years, and in 1998 she started working at the University of São Paulo.
Her research has focused on the neural mechanisms in the pathogenesis of experimental hypertension and diabetes. Recently she has developed scientific projects involving human physiology, especially in the area of pathophysiology of cardiovascular diseases and hypertension. She has published over 200 peer reviewed manuscripts.
She currently serves as chair of the Publications Committee of IASH and as advisor to various agencies of scientific funding in Brazil as CNPq, CAPES and FAPESP. She was President of the Brazilian Society of Hypertension during 2010-2012 period.Dr. Irigoyen is currently a Fellow of the National Council for Scientific and Technological Development (CNPq). She has received several awards including Inter-American Society of Hypertension Young Investigator Award, the Brazilian Society of Hypertension (Eduardo Moacyr Krieger Award for Scientific Development), and Brazilian Society of Physiology Award. Dr. Irigoyen´s research has been continuously funded by CNPq, CAPES and FAPESP.
Associate Professor of the Department of Physiology, Tulane University, New Orleans, LA. Dr. Prieto teaches Physiology in the School of Medicine and is an active investigator in the cardiovascular field. Her research focuses on renal mechanisms of control of blood pressure in health and hypertension. Her published work deals with the mechanisms regulating renin and the prorenin receptor in the distal nephron and consequences of their interaction on the development and progression of hypertension and kidney injury. Prieto has served as reviewer of the AHA and NIH, several editorial boards, and a number of journals, including AJP Renal Physiology, AJP Regulatory, Integrative and Comparative Physiology, Hypertension, JASN, Journal of Hypertension, and PlosOne to name a few. She is currently the Secretary of the AJP Renal Section and the Editor of the Physiological Genomics Group of Interest Newsletter. Dr. Prieto is member of the AHA, ASN, AFMR, ASH, and IASH. Prieto has received several prestigious awards. Among the most prestigious, the Caroline tum Suden/Francis Hellebrandt Professional Opportunity Award from the APS (2004), the Excellence in Research Award from the APS Renal Section (2005), the Young Investigator Recognition Award from the Water & Electrolyte Homeostasis Section of the APS (2005), the Arthur C. Guyton New Investigator Award from the Consortium of Southern States Hypertension Council (2005), the Merck New Investigator Award/Latin America from the AHA (2006), the Research Enhancement Career Award from the APS (2007), and the Young Scholars Award by the ASH (2008). She is a Fellow of the AHA of the CHBPR since 2008 and is currently funded by the NIH-NIDDK and the LACaTs. Prieto received her M.D and M.S in Molecular Genetics from the University of Zulia (Venezuela) and her Ph.D in Renal Physiology from TulaneUniversity in 2004.
Began his career as Director of Continuing Education at the University of Pittsburgh Regional Medical Program and as Instructor in Community Medicine. He then moved to the University of Michigan Medical School and School of Public Health as Assistant Professor. In 1978 he joined the National Institutes of Health in Bethesda, Maryland as Coordinator of the National High Blood Pressure Education Program (NHBPEP). There he directed the NHBPEP public, patient and professional activities, which have been cited to improve the nation’s hypertension profile and contributed to the nations large decline in cardiovascular disease. As NHBPEP Coordinator, he organized 47 professional, voluntary and official organizations into one body, which developed national clinical guidelines for prevention and treatment of hypertension, including the Joint National Committee (JNC) reports. He led United States scientific delegations regarding the prevention and treatment of hypertension to Brazil, Germany, Egypt and Jordan. Dr. Roccella has authored 110 publications in scientific journals and textbooks dealing with prevention and control of high blood pressure, patient education, public health approaches to improving cardiovascular health and evaluating large-scale public health programs. He is a past president of the Society for Public Health Education. Dr. Roccella has been awarded the National Institutes of Health Directors Award, the HealthTrac Foundation Prize, the University of Michigan John Romani Prize for lifetime achievement in public health administration, the American Society of Hypertension Presidents Award, the International Society of Hypertension in Blacks Presidential Award, the Society for Public Health Education Distinguished Fellow, the 2008 Senator Frank Laughtenberg Award and the Consortium for Southeast Hypertension Control Presidential and Lifetime Achievement Awards. He retired from the National Institutes of Health in 2007 and remains active in the cardiovascular disease prevention and control field.
Has a Pharm. D. degree from the School of Pharmaceutical Sciences of Ribeirao Preto – University of Sao Paulo, Ribeirao Preto, Brazil (February 2002 – December 2006). She also pursues a Ph.D. degree in Pharmacology from the School of Medical Sciences – State University of Campinas, Campinas, Brazil (February 2007 – March 2010). Following her graduation, Dr. Palei joined the Department of Physiology and Biophysics of the University of Mississippi Medical Center (UMMC) for a post-doctoral training in cardiovascular-renal research under the supervision of Dr. Joey P. Granger (April 2011 – December 2013). In 2014, she was promoted to instructor of the same department. Dr. Palei’s current research focuses on the role of obesity and other metabolic factors in the pathogenesis of preeclampsia. She uses different animal models of obesity and pregnancy-induced hypertension to study mechanisms whereby obesity increases the risk for developing preeclampsia and potential therapeutic targets that may help the development of better tools to early diagnose, prevent and/or treat preeclampsia. Dr. Palei has authored over 50 peer reviewed papers on different topics of cardiovascular research. She is a member of the American Heart Association, American Physiological Society, International Society of Hypertension, and Brazilian Society for Pharmacology and Experimental Therapeutics. Among other awards, Dr. Palei is a recipient of the 2014 American Heart Association Postdoctoral Fellowship, 2014 and 2011 New Investigator Travel Award from the Inter-American Society of Hypertension, 2012 Caroline tum Suden Professional Opportunity Award and 2012 NIDDK Minority Travel Fellowship Award from the American Physiological Society, and 2010 Boehringer Ingelheim Young Investigator Travel Award from the American Society of Hypertension. In addition, she serves as Chair of the Trainee Committee of the Inter-American Society of Hypertension, as a member of the Postdoctoral Advisory Committee at UMMC, and as reviewer of different international scientific journals.
Jeffrey Garvin, Ph.D. is currently Professor of Physiology and Biophysics at Case Western Reserve University. He received his B.S. from the University of Miami in Biology and Chemistry in 1979 and his Ph.D. from Duke University in 1984. Dr. Garvin did his postdoctoral training in the Laboratory of Kidney and Electrolyte Metabolism at the National Institutes of Health under Maurice Burg, Mark Knepper and Kenneth Spring where he was supported by a National Kidney Foundation fellowship and two National Research Service Awards. In 1988 he joined the Hypertension and Vascular Research Division of Henry Ford Hospital and became Division Head in 2009. He moved to Case Western Reserve University in 2012. His research deals with the regulation of transport processes in the kidney and how disregulation of these systems contributes to hypertension. Currently he has more than 140 original publications on renal physiology. Dr. Garvin has served on numerous editorial boards and study sections, and was an Associate Editor of The American Journal of Physiology: Renal Physiology. He has received a number of awards for his work including the Lewis K. Dahl Award from the American Heart Association and the Carl W. Gottschalk Award from the American Physiological Society. Dr. Garvin was Chair of the NIH’s Kidney Molecular Biology and Development study section and is a fellow of the Council on Hypertension of the American Heart Association and was a member of its Leadership Committee. He is also a member of the Kidney Council.